ClinicalTrials.gg
CompletedNCT05759949Updated May 16, 2025

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

A Phase 1 interventional study of RLY-5836 and Fulvestrant in PIK3CA Mutation, Solid Tumor, Adult and HER2-negative Breast Cancer, sponsored by Relay Therapeutics, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Relay Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know · 12 judgments

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1, first-in-human, open-label study designed to evaluate the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RLY-5836 in advanced solid tumors in participants harboring a PIK3CA mutation in blood and/or tumor per local assessment. The study consists of 2 parts, a dose escalation (Part 1) and a dose expansion (Part 2).

02

Conditions studied

  • PIK3CA Mutation
  • Solid Tumor, Adult
  • HER2-negative Breast Cancer
  • Breast Cancer
  • Metastatic Breast Cancer
  • Advanced Breast Cancer
  • Unresectable Solid Tumor
  • Hormone Receptor Positive Tumor

Browse trials for

03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 41 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Relay Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient has performance status of 0-1

One or more documented primary oncogenic PIK3CA mutation(s) in blood and/or tumor per local assessment

RLY-5836 single agent arm key inclusion criteria

  • Disease that is to standard therapy, intolerant to standard therapy, or participant has declined standard therapy.
  • A or cytologically confirmed diagnosis of unresectable or solid tumor

Combination arms key inclusion criteria

  • Males, females, or pre-/perimenopausal females previously treated with gonadotropin-releasing GnRH agonist at least 4 weeks prior to start of study drug with histologically or cytologically confirmed diagnosis of HR+, - unresectable or metastatic breast cancer that is not amenable to curative therapy.
  • Had previous treatment for advanced or metastatic breast cancer with antiestrogen therapy including, but not limited to, selective estrogen receptor degraders (e.g., fulvestrant), selective estrogen receptor modulators (e.g., tamoxifen), and aromatase inhibitors (AI) (letrozole, anastrozole, exemestane)
  • Part 1: Prior PI3Kα inhibitor treatment is allowed if taken for \< 14 days and not discontinued due to disease progression, , or ≥ Grade 3 TEAEs.

Exclusion criteria

Exclusion Criteria:

  • Part 2: Prior treatment with PI3Kα inhibitors.
  • Type 1 or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥140 mg/dL and glycosylated () ≥7.0%.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    RLY-5836 Single Agent Arm

    RLY-5836 single agent arm for participants with unresectable or metastatic solid tumors

    Drug: RLY-5836

  • Experimental
    RLY-5836 + Fulvestrant Arm

    RLY-5836 + fulvestrant combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer

    Drug: RLY-5836 · Drug: Fulvestrant

  • Experimental
    RLY-5836 + Palbociclib + Fulvestrant Arm

    RLY-5836 + palbociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer

    Drug: RLY-5836 · Drug: Fulvestrant · Drug: Palbociclib

  • Experimental
    RLY-5836 + Ribociclib + Fulvestrant Arm

    RLY-5836 + ribociclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer

    Drug: RLY-5836 · Drug: Fulvestrant · Drug: Ribociclib

  • Experimental
    RLY-5836 + Abemaciclib + Fulvestrant Arm

    RLY-5836 + abemaciclib + fulvestrant triple combination arm for participants with HR+, HER2- locally advanced or metastatic breast cancer

    Drug: RLY-5836 · Drug: Fulvestrant · Drug: Abemaciclib

Interventions

  • DrugRLY-5836

    RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.

  • Fulvestrant (500 mg) is administered IM into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as 2×5 mL injections, 1 in each buttock, on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of each subsequent cycle.

    Also known as: Faslodex

  • Palbociclib 125 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

    Also known as: Ibrance

  • Ribociclib 600 mg once daily is taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.

    Also known as: Kisqali

  • Abemaciclib 150 mg BID will be taken orally in combination with RLY-5836 and fulvestrant for 28-day cycles.

    Also known as: Verzenio

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of RLY-5836

    Time frame: Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months

  2. Number of participants with any dose-limiting toxicity (DLT)

    Time frame: Cycle 1, up to 28 days.

  3. Number of participants with adverse events (AEs)

    Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months

  4. Number of participants with serious adverse events (SAEs)

    Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 24 months

Secondary outcomes

  1. PIK3CA genotype in blood and tumor tissue by next generation nucleic acid sequencing

    Time frame: Every cycle (4-week cycles) through Cycle 3 and every other cycle thereafter until study discontinuation, approximately 24 months

  2. PK of RLY-5836: area under the concentration-time curve (AUC)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through end of treatment (4-week cycles), approximately 24 months

  3. PK of RLY-5836: maximum plasma concentration (Cmax)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through end of treatment (4-week cycles), approximately 24 months

  4. PK of RLY-5836: time to maximum concentration (tmax)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through end of treatment (4-week cycles), approximately 24 months

  5. PK of RLY-5836: half-life (t½)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through end of treatment (4-week cycles), approximately 24 months

  6. PK of RLY-5836: clearance following oral dose (CL/F)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through end of treatment (4-week cycles), approximately 24 months

  7. Changes in circulating markers of glucose metabolism: changes in circulating glucose

    Time frame: Approximately every week in Cycle 1 (4-week cycle), every 2 weeks in Cycle 2 (4-week cycle), and every cycle through end of treatment (4-week cycles), approximately 24 months

  8. Changes in circulating markers of glucose metabolism: changes in circulating insulin

    Time frame: Approximately every week in Cycle 1 (4-week cycle), every 2 weeks in Cycle 2 (4-week cycle), and every cycle through end of treatment (4-week cycles), approximately 24 months

  9. Changes in circulating markers of glucose metabolism: changes in circulating C-peptide

    Time frame: Approximately every week in Cycle 1 (4-week cycle), every 2 weeks in Cycle 2 (4-week cycle), and every cycle through end of treatment (4-week cycles), approximately 24 months

  10. Changes in circulating markers of glucose metabolism: changes in circulating glycosylated hemoglobin [HbA1c]

    Time frame: Approximately every week in Cycle 1 (4-week cycle), every 2 weeks in Cycle 2 (4-week cycle), and every cycle through end of treatment (4-week cycles), approximately 24 months

  11. Preliminary antitumor activity of RLY-5836: duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)

    Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months

  12. Preliminary antitumor activity of RLY-5836: disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)

    Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months

  13. Preliminary antitumor activity of RLY-5836: objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)

    Time frame: Approximately every 8 weeks until progressive disease, approximately 36 months

07

Study locations

7 sites
  • Sarah Cannon Research Institute at Florida Cancer Specialists
    Orlando, Florida 32827, United States
  • Community Cancer Center North
    Indianapolis, Indiana 46250, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Memorial Sloan Kettering Cancer Center-Main Campus
    New York, New York 10065, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2025, 23 months.

Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 23 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Mar 8, 2023
StartActual
Mar 29, 2023
Primary completionActual
Mar 18, 2025
CompletionActual
Apr 11, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05759949
Lead sponsor
Relay Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Mar 29, 2023
Primary completion
Mar 18, 2025
Completion
Apr 11, 2025
Last update
May 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion